{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:16:38Z","timestamp":1789103798787,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007145"],"award-info":[{"award-number":["INV-007145"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although viral suppression is attained for most adults living with diagnosed HIV in East, Central, Southern and West Africa\u00a0(ECSWA), challenges remain with sustained adherence to daily oral pill taking for some in the population. Here, we evaluate the potential effectiveness and cost-effectiveness of introduction of a new combination of long-acting injectable drugs of lenacapavir\u2009+\u2009cabotegravir to increase levels of sustained viral suppression. We find there is potential for a significant impact on HIV deaths and disability adjusted life years, including due to a decrease in mother to child transmission. If lenacapavir\u2009+\u2009cabotegravir can be sourced at a cost of around $\u200980 per year or less, our analysis suggests there is potential for a policy to introduce it to be cost-effective in settings in ECSWA. Recognising the limitations of a modelling study, we suggest that implementation studies be conducted to confirm the viability of these approaches.<\/jats:p>","DOI":"10.1038\/s41467-025-60752-y","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:15:39Z","timestamp":1751357739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2384-4807","authenticated-orcid":false,"given":"Andrew","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loveleen","family":"Bansi-Matharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenly","family":"Sikwese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Flexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vitoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zack","family":"Panos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ripin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8913-1602","authenticated-orcid":false,"given":"Matthew","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Havlir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-1994","authenticated-orcid":false,"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Revill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60752_CR1","unstructured":"UNAIDS. 2024 Gobal AIDS Report \u2014 The Urgency of Now: AIDS at a Crossroads. https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/global-aids-update-2024 (2024)."},{"key":"60752_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.2016.5148","volume":"316","author":"AJ Rodger","year":"2016","unstructured":"Rodger, A. J. et al. Sexual activity without condoms and risk of HIV transmission in sero-different couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 316, 171\u2013181 (2016).","journal-title":"JAMA"},{"key":"60752_CR3","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","volume":"10","author":"JB Nachega","year":"2023","unstructured":"Nachega, J. B. et al. Long-acting antiretrovirals and HIV treatment adherence.  Lancet HIV 10, e332\u2013e342 (2023).","journal-title":"Lancet HIV"},{"key":"60752_CR4","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s10461-022-03949-2","volume":"27","author":"E Toska","year":"2023","unstructured":"Toska, E. et al. Factors associated with preferences for long-acting injectable antiretroviral therapy among adolescents and young people living with HIV in South Africa. AIDS Behav. 27, 2163\u20132175 (2023).","journal-title":"AIDS Behav."},{"key":"60752_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/25787489.2020.1824718","volume":"21","author":"M Murray","year":"2020","unstructured":"Murray, M. et al. Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial. HIV Res. Clin. Pract. 21, 105\u2013113 (2020).","journal-title":"HIV Res. Clin. Pract."},{"key":"60752_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","volume":"14","author":"V Chounta","year":"2021","unstructured":"Chounta, V. et al. Patient-reported outcomes through 1\u2009year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8\u2009weeks (ATLAS-2M). Patient 14, 849\u2013862 (2021).","journal-title":"Patient"},{"key":"60752_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09309-w","volume":"24","author":"A Kaggiah","year":"2024","unstructured":"Kaggiah, A. et al. Key informant views on potential acceptability and feasibility of long-acting antiretroviral treatment for HIV in Kenya. BMC Infect. Dis. 24, 415 (2024).","journal-title":"BMC Infect. Dis."},{"key":"60752_CR8","doi-asserted-by":"publisher","first-page":"e0234666","DOI":"10.1371\/journal.pone.0234666","volume":"15","author":"D Kerrigan","year":"2020","unstructured":"Kerrigan, D. et al. A dream come true\u201d: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLoS ONE 15, e0234666 (2020).","journal-title":"PLoS ONE"},{"key":"60752_CR9","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1093\/cid\/ciac752","volume":"75","author":"C Kityo","year":"2022","unstructured":"Kityo, C., Cortes, C. P., Phanuphak, N., Grinsztejn, B. & Venter, F. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of hiv in low- and middle-income countries (LMICs). Clin. Infect. Dis. 75, S549\u2013S556 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"60752_CR10","doi-asserted-by":"crossref","unstructured":"Hickey, M. D. et al. 48\u2009week viral suppression rates in people with HIV starting long-acting CAB\/RPV with initial viremia. Clin. Infect. Dis. 80, 864\u2212870 (2024).","DOI":"10.1093\/cid\/ciae500"},{"key":"60752_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","volume":"96","author":"M Hickey","year":"2024","unstructured":"Hickey, M. et al. Identifying implementation determinants and strategies for long-acting injectable cabotegravir\u2013rilpivirine in people with HIV who are virally unsuppressed. JAIDS J. Acquir. Immune Defic. Syndr. 96, 280\u2013289 (2024).","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"60752_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/M23-0788","volume":"176","author":"M Gandhi","year":"2023","unstructured":"Gandhi, M. et al. Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV. Ann. Intern. Med. 176, 969\u2013974 (2023).","journal-title":"Ann. Intern. Med."},{"key":"60752_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAI.0000000000003396","volume":"96","author":"NJ Mehtani","year":"2024","unstructured":"Mehtani, N. J. et al. Feasibility of implementing a low-barrier long-acting injectable antiretroviral program for HIV treatment and prevention for people experiencing homelessness. J. Acquir Immune Defic. Syndr. 96, 61\u201367 (2024).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"60752_CR14","unstructured":"Jan, B. et al. 6\u2009Month Outcomes of Every 2\u2009Months Long-Acting Cabotegravir and Rilpivirine in a Real-World Setting \u2013 Effectiveness, Adherence to Injections, and Patient- Reported Outcomes of People Living With HIV in the German CARLOS Cohort. https:\/\/medinfo.gsk.com (2022)."},{"key":"60752_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.059","volume":"10","author":"RK Hsu","year":"2023","unstructured":"Hsu, R. K. et al. 1028. Real-world use of long-acting cabotegravir + rilpivirine in people with HIV with detectable viral loads at initiation: findings from the OPERA\u00ae cohort. Open Forum Infect. Dis. 10, ofad500.059 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"60752_CR16","unstructured":"Gaur et al. Long-acting Cabotegravir Plus Rilpivirine in Adolescents with HIV: Week 24 IMPAACT 2017 (MOCHA) Study. Conference on Retroviruses and Opportunistic Infections in Denver, Colorado. https:\/\/www.impaactnetwork.org\/studies\/impaact2017 (2024)."},{"key":"60752_CR17","unstructured":"Rana et al. Long-acting injectable CAB\/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359. In Conference on Retroviruses and Opportunistic Infections in Denver, Colorado 1\u22126 (NATAP, 2024)."},{"key":"60752_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells, S. et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N. Engl. J. Med. 382, 1112\u20131123 (2020).","journal-title":"N. Engl. J. Med."},{"key":"60752_CR19","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin, C. et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N. Engl. J. Med. 382, 1124\u20131135 (2020).","journal-title":"N. Engl. J. Med."},{"key":"60752_CR20","unstructured":"NICE. National Institute For Health And Care Excellence. Cabotegravir With Rilpivirine For Treating HIV-1. https:\/\/www.nice.org.uk\/guidance\/ta757\/chapter\/1-Recommendations (2022)."},{"key":"60752_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","volume":"24","author":"C Kityo","year":"2024","unstructured":"Kityo, C. et al. CARES trial team. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect. Dis. 24, 1083\u20131092 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"60752_CR22","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jama.2024.2985","volume":"331","author":"PE Sax","year":"2024","unstructured":"Sax, P. E., Thompson, M. A. & Saag, M. S. Panel I-UTG. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel. JAMA 331, 1060\u20131061 (2024).","journal-title":"JAMA"},{"key":"60752_CR23","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv (2024)"},{"key":"60752_CR24","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1016\/S2214-109X(21)00025-5","volume":"9","author":"AN Phillips","year":"2021","unstructured":"Phillips, A. N. et al. The potential role of long-acting injectable cabotegravir\u2013rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. Lancet Glob. Health 9, e620\u2013e627 (2021).","journal-title":"Lancet Glob. Health"},{"key":"60752_CR25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"LG Bekker","year":"2024","unstructured":"Bekker, L. G. et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N. Engl. J. Med. 391, 1179\u20131192 (2024).","journal-title":"N. Engl. J. Med."},{"key":"60752_CR26","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer, S. et al. CAPELLA Study investigators. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med. 386, 1793\u20131803 (2022).","journal-title":"N. Engl. J. Med."},{"key":"60752_CR27","doi-asserted-by":"crossref","unstructured":"Ogbuagu, O. et al. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV-1: week 104 results of a phase 2\/3 trial. Clin. Infect. Dis. 80, 566\u2212574 (2024).","DOI":"10.1093\/cid\/ciae423"},{"key":"60752_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae125","volume":"11","author":"M Gandhi","year":"2024","unstructured":"Gandhi, M. et al. Case series of people with HIV on the long-acting combination of lenacapavir and cabotegravir: call for a trial. Open Forum Infect. Dis. 11, ofae125 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"60752_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-018-0214-y","volume":"16","author":"D Bukenya","year":"2019","unstructured":"Bukenya, D. et al. What causes non-adherence among some individuals on long term antiretroviral therapy? experiences of individuals with poor viral suppression in Uganda. AIDS Res. Ther. 16, 2 (2019).","journal-title":"AIDS Res. Ther."},{"key":"60752_CR30","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/tmi.13473","volume":"25","author":"HS Jones","year":"2020","unstructured":"Jones, H. S. et al. HPTN 071 (PopART) Study Team. Association between HIV stigma and antiretroviral therapy adherence among adults living with HIV: baseline findings from the HPTN 071 (PopART) trial in Zambia and South Africa. Trop. Med. Int. Health 25, 1246\u20131260 (2020).","journal-title":"Trop. Med. Int. Health"},{"key":"60752_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.drugalcdep.2010.06.014","volume":"112","author":"MM Azar","year":"2010","unstructured":"Azar, M. M., Springer, S. A., Meyer, J. P. & Altice, F. L. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 112, 178\u2013193 (2010).","journal-title":"Drug Alcohol Depend."},{"key":"60752_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30451-z","volume":"13","author":"P Arashiro","year":"2023","unstructured":"Arashiro, P. et al. Adherence to antiretroviral therapy in people living with HIV with moderate or severe mental disorder. Sci. Rep. 13, 3569 (2023).","journal-title":"Sci. Rep."},{"key":"60752_CR33","unstructured":"United Nations. Department of Economic and Social Affairs, Population Division World Family Planning 2022: Meeting the changing needs for family planning: Contraceptive use by Age and Method. https:\/\/www.un.org\/development\/desa\/pd\/sites\/www.un.org.development.desa.pd\/files\/files\/documents\/2023\/Feb\/undesa_pd_2022_world-family-planning.pdf (2022)."},{"key":"60752_CR34","unstructured":"Clinical Info. Re commendations for the Use of Antire troviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal\/safety-toxicity-arv-agents-integrase-inhibitors-cabotegravir-vocabria#:~:text=No%20congenital%20anomalies%2C%20preterm%20births,IM%20injections%20of%20CAB%20alone (2024)."},{"key":"60752_CR35","first-page":"1","volume":"16","author":"C Marzolini","year":"2024","unstructured":"Marzolini, C., Gibbons, S., Seddon, D. & Khoo, S. Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir. Expert Opin. Drug Metab. Toxicol. 16, 1\u201312 (2024).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"60752_CR36","unstructured":"Stanford University HIV Drug Resistance Database. INSTI Resistance Notes. https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/INSTI\/ (2025)."},{"key":"60752_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jac\/dkac388","volume":"78","author":"AD Nka","year":"2022","unstructured":"Nka, A. D. et al. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals. J. Antimicrob. Chemother. 78, 272\u2013275 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"60752_CR38","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/jac\/dkae115","volume":"79","author":"M Wirden","year":"2024","unstructured":"Wirden, M. et al. Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3\u2009weeks on lenacapavir. J. Antimicrob. Chemother. 79, 1706\u20131707 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"60752_CR39","doi-asserted-by":"crossref","unstructured":"Han K. et al. Population pharmacokinetic (PPK) modeling and simulation of long-acting (LA) cabotegravir (CAB) to inform strategies following dosing interruptions in HIV-1 infected subjects. Open Forum Infect. Dis. 6, S558 (2019).","DOI":"10.1093\/ofid\/ofz360.1396"},{"key":"60752_CR40","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","volume":"60","author":"D Hodge","year":"2021","unstructured":"Hodge, D., Back, D. J., Gibbons, S., Khoo, S. H. & Marzolini, C. Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin. Pharmacokinet. 60, 835\u2013853 (2021).","journal-title":"Clin. Pharmacokinet."},{"key":"60752_CR41","unstructured":"Han, K. et al. Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports\u2009\u2265\u20094\u2009Monthly Dose Interval. https:\/\/www.croiconference.org\/abstract\/phase-i-study-of-cabotegravir-long-acting-injectable formulations-supports-%E2%89%A54-monthly-dose-interval\/ (2024)."},{"key":"60752_CR42","doi-asserted-by":"publisher","first-page":"e1648","DOI":"10.1016\/S2214-109X(23)00383-2","volume":"11","author":"AN Philips","year":"2023","unstructured":"Philips, A. N. et al. Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis. Lancet Glob. Health 11, e1648\u2013e1657 (2023).","journal-title":"Lancet Glob. Health"},{"key":"60752_CR43","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe, S. et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.  Lancet 399, 1779\u20131789 (2022).","journal-title":"Lancet"},{"key":"60752_CR44","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00365-4","volume":"10","author":"J Smith","year":"2023","unstructured":"Smith, J. et al. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV 10, e254\u2013e265 (2023).","journal-title":"Lancet HIV"},{"key":"60752_CR45","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1093\/jac\/dkae305","volume":"79","author":"A Hill","year":"2024","unstructured":"Hill, A. et al. Lenacapavir to prevent HIV infection: current prices versus estimated costs of production. J. Antimicrob. Chemother. 79, 2906\u20132915 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"60752_CR46","unstructured":"CHAI. Understanding Manufacturing And Cost For HIV Prevention Game Changer: Generic CAB-LA COGS Analysis and FAQ Brief. https:\/\/www.clintonhealthaccess.org\/blog\/understanding-manufacturing-and-cost-for-hiv-prevention-game-changer-generic-cab-la-cogs-analysis-and-faq-brief\/ (2023)."},{"key":"60752_CR47","unstructured":"Gilead Sciences. Updated Statement on Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention. https:\/\/www.gilead.com\/company\/company-statements\/2024\/updated-statement-on-access-planning-in-high-incidence-resource-limited-countries-for-lenacapavir-for-hiv-prevention (2025)."},{"key":"60752_CR48","doi-asserted-by":"publisher","first-page":"e000964","DOI":"10.1136\/bmjgh-2018-000964","volume":"3","author":"J Ochalek","year":"2018","unstructured":"Ochalek, J., Lomas, J. & Claxton, K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob. Health 3, e000964 (2018).","journal-title":"BMJ Glob. Health"},{"key":"60752_CR49","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S2352-3018(17)30190-X","volume":"5","author":"AN Phillips","year":"2018","unstructured":"Phillips, A. N. et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV 5, e146\u2013e154 (2018).","journal-title":"Lancet HIV"},{"key":"60752_CR50","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","volume":"6","author":"AN Phillips","year":"2019","unstructured":"Phillips, A. N. et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV 6, e116\u2013e127 (2019).","journal-title":"Lancet HIV"},{"key":"60752_CR51","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S2352-3018(19)30400-X","volume":"7","author":"AN Phillips","year":"2020","unstructured":"Phillips, A. N. et al. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV 7, e193\u2013e200 (2020).","journal-title":"Lancet HIV"},{"key":"60752_CR52","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods, B., Revill, P., Sculpher, M. & Claxton, K. Country-Level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health 19, 929\u2013935 (2016).","journal-title":"Value Health"},{"key":"60752_CR53","unstructured":"Claxton, K. et al. Informing Decisions in Global Health: Cost Per DALY Thresholds and Health Opportunity Costs. https:\/\/www.york.ac.uk\/media\/che\/documents\/policybriefing\/Cost%20per%20DALY%20thresholds.pdf (2024)."},{"key":"60752_CR54","unstructured":"CHAI. 2023 HIV Market Report: The State of the HIV Market in Low- and Middle-Income Countries. https:\/\/www.clintonhealthaccess.org\/report\/2023-hiv-market-report-the-state-of-hiv-market-in-low-and-middle-income-countries\/ (2023)."},{"key":"60752_CR55","doi-asserted-by":"crossref","unstructured":"Rosen, S. et al. Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019. Gates Open Res. 5, 177 (2022).","DOI":"10.12688\/gatesopenres.13458.2"},{"key":"60752_CR56","unstructured":"Population Health Impact Assessments. PHIA PROJECT Key data to guide the global response to the HIV epidemic https:\/\/phia.icap.columbia.edu\/ (2024)."}],"updated-by":[{"DOI":"10.1038\/s41467-026-72202-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60752-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:30:47Z","timestamp":1776490247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60752-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60752"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60752-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-026-72202-4","URL":"https:\/\/doi.org\/10.1038\/s41467-026-72202-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H.: for the NIH funded SEARCH study, ViiV provided cabotegravir for the study. C.F. served as an expert witness for a law firm representing Gilead in a patent dispute in 2023. Payments came from the law firm and not from Gilead, and the payments were not contingent on outcome. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5760"}}